United Therapeutics (NASDAQ:UTHR) shares rose 13% to $543.99 after a Delaware federal court denied Liquidia’s motion to strike a defense argument in a patent infringement case involving Tyvaso and Yutrepia.
Tiziana Life Sciences (NASDAQ:TLSA) submitted a request to the U.S. Food and Drug Administration for Orphan Drug Designation for intranasal foralumab as a potential treatment for multiple system atrophy (MSA).
Kailera Therapeutics (NASDAQ:KLRA) announced completion of enrollment across three global Phase 3 trials evaluating investigational once-weekly ribupatide injection in people with obesity or overweight.
Jade Biosciences (NASDAQ:JBIO) reported preclinical results for JADE301, an investigational antibody targeting dermatomyositis, at the European Academy of Dermatology and Venereology Congress in Vienna.
Connect Biopharma (NASDAQ:CNTB) reported preliminary Phase 2 results showing that investigational rademikibart reduced treatment failure in adults with acute chronic obstructive pulmonary disease (COPD) exacerbations and type 2 inflammation.
NRx Pharmaceuticals (NASDAQ:NRXP) announced that its subsidiary NRx Defense Systems received an initial DARPA prime contract worth $11,177,757.27 to evaluate a treatment approach for major depressive disorder.
Atara Biotherapeutics (NASDAQ:ATRA) announced that partner Pierre Fabre Pharmaceuticals resubmitted the Biologics License Application (BLA) for tabelecleucel to the U.S. Food and Drug Administration for treatment of relapsed or refractory EBV-positive post-transplant lymphoproliferative disease.
Cerenome (NASDAQ:CNSY) reported unaudited third-quarter 2026 gross payer billings of $1.55 million from 222 tests performed by its wholly owned CNSide Diagnostics subsidiary.
Sarepta Therapeutics (NASDAQ:SRPT) presented new clinical data showing ELEVIDYS (delandistrogene moxeparvovec) was associated with functional benefits in older ambulatory patients with Duchenne muscular dystrophy at the World Muscle Society Congress 2026.
Novo Nordisk (NYSE:NVO) presented new CagriSema clinical data at EASD 2026, including studies evaluating food-related brain responses, organ fat changes and weight reduction in adults with overweight or obesity.
Merck (NYSE:MRK) reported Phase 2b MK-7240-012 trial results showing investigational tulisokibart achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 in patients with moderate to severe hidradenitis suppurativa.
Eli Lilly (NYSE:LLY) reported Phase 3b ADtouch study results showing EBGLYSS monotherapy met its primary and secondary endpoints in adults and adolescents with hand-and-foot atopic dermatitis.
-640x360.webp&w=3840&q=75)
